Related Experiment Video

Updated: Jul 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Stage I seminoma and carboplatin risks

A Horwich

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |January 30, 2008
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    Related Experiment Videos

    Last Updated: Jul 7, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    Related Concept Videos

    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019

    ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018

    The ESMO guideline strategy: an identity statement and reflections on improvement.

    Annals of oncology : official journal of the European Society for Medical Oncology·2015

    Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.

    British journal of cancer·2015

    Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014

    Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma.

    British journal of cancer·2013

    SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    A Novel 7 Sialylation-Related LncRNA Signature as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.

    Current medicinal chemistry·2026

    Prediction of meningioma shrinkage after cyproterone acetate cessation.

    Neuro-oncology advances·2026

    Risk of colorectal cancer incidence and mortality after removals of polyps: a cohort study using the UK Biobank.

    Annals of gastroenterology·2026

    In vivo assessment of melanoma based on photoacoustic absorption and viscoelasticity imaging.

    Biomedical optics express·2026

    High-sensitivity Raman spectroscopy for prostate cancer detection and tissue extraction guidance.

    Biomedical optics express·2026

    Development and validation of a multimodal interpretable machine learning model for the identification of osteoporosis in patients with type 2 diabetes mellitus: a multicenter retrospective study.

    Frontiers in endocrinology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us